Application of the dual-tail approach for the design and synthesis of novel Thiopyrimidine-Benzenesulfonamide hybrids as selective carbonic anhydrase inhibitors

被引:37
作者
Abdel-Mohsen, Heba T. [1 ]
El Kerdawy, Ahmed M. [2 ,3 ]
Omar, Mohamed A. [1 ]
Petreni, Andrea [4 ]
Allam, Rasha M. [5 ]
El Diwani, Hoda, I [1 ]
Supuran, Claudiu T. [4 ]
机构
[1] Natl Res Ctr, Pharmaceut & Drug Ind Res Inst, Dept Chem Nat & Microbial Prod, El Buhouth St,POB 12622, Cairo, Egypt
[2] Cairo Univ, Fac Pharm, Dept Pharmaceut Chem, Kasr El Aini St,POB 11562, Cairo, Egypt
[3] Newgiza Univ NGU, Sch Pharm, Dept Pharmaceut Chem, Km 22 CairoAlexandria Desert Rd, Cairo, Egypt
[4] Univ Firenze, Pharmaceut & Nutraceut Sect, Dept NEUROFARBA, Via Ugo Schiff 6, I-50019 Florence, Italy
[5] Natl Res Ctr, Dept Pharmacol, El Buhouth St,POB 12622, Cairo, Egypt
关键词
Dual-tail approach; Thiopyrimidine-benzenesulfonamide hybrids; Carbonic anhydrase inhibitors; Antiproliferative activity; CANCER; IX; SULFONAMIDES; EXPRESSION; CHEMISTRY; BIOMARKER; MOIETIES; HYPOXIA; POTENT;
D O I
10.1016/j.ejmech.2021.114004
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A dual-tail approach was applied to the design of a novel series of 2-thiopyrimidine-benzenesulfonamides as carbonic anhydrase (CA) inhibitors. The design strategy is based on the hybridization between a benzenesulfonamide moiety as Zn2+ binding group and 2,4-disubstituted thio-pyridimidine as a tail. Among the synthesized compounds, 14h displayed the highest potency (K-i = 1.72 nM) and selectivity for CA II over the isoforms CA IX and CA XII with selectivity indexes of 50 and 5.26, respectively. Meanwhile, compounds 14a and 141 displayed a potent inhibitory activity against CA IX (K-i = 7.4 and 7.0 nM, respectively) compared with the reference drug acetazolamide (AAZ) (K-i = 25 nM), and compound 141 showed higher potency (K-i = 4.67 nM) than AAZ (K-i = 5.7 nM) against the tumor-associated isoform CA XII. Evaluation of the antiproliferative activity in NCI single-dose testing of selected hybrids revealed a pronounced potency of the selective CA II inhibitor 14h against most of the tested NCI cancer cell lines. Moreover, compound 14h demonstrated an IC50 values ranging from 2.40 to 4.50 mu M against MCF-7, T-47D, MDA-MB-231, HCT-116, HT29 and SW-620. These results demonstrate that CA II inhibition can be an alternative therapeutic target for cancer treatment. A cell cycle analysis of MCF-7 and MDA-MB-231 showed that treatment with 14h arrested both cell lines at the G2/M phase with significant accumulation of cells in the pre-G1 phase. Moreover, compound 14h showed a noticeable induction of late apoptosis and necrotic cell death of both cell lines compared with untreated cells as a control. A molecular docking study suggested that the sulfonamide moiety accommodates deeply in the CA active site and interacts with the Zn2+ ion while the dual-tail extension interacts with the surrounding amino acids via several hydrophilic and hydrophobic interactions, which affects the potency and selectivity of the hybrids. (C) 2021 Elsevier Masson SAS. All rights reserved.
引用
收藏
页数:21
相关论文
共 54 条
  • [1] Laccase-catalyzed green synthesis and cytotoxic activity of novel pyrimidobenzothiazoles and catechol thioethers
    Abdel-Mohsen, H. T.
    Conrad, J.
    Harms, K.
    Nohr, D.
    Beifuss, U.
    [J]. RSC ADVANCES, 2017, 7 (28) : 17427 - 17441
  • [2] New thiopyrimidine-benzenesulfonamide conjugates as selective carbonic anhydrase II inhibitors: synthesis, in vitro biological evaluation, and molecular docking studies
    Abdel-Mohsen, Heba T.
    El Kerdawy, Ahmed M.
    Omar, Mohamed A.
    Berrino, Emanuela
    Abdelsamie, Ahmed S.
    El Diwani, Hoda, I
    Supuran, Claudiu T.
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY, 2020, 28 (05)
  • [3] New 2,4-disubstituted-2-thiopyrimidines as VEGFR-2 inhibitors: Design, synthesis, and biological evaluation
    Abdel-Mohsen, Heba T.
    Girgis, Adel S.
    Mahmoud, Abeer E. E.
    Ali, Mamdouh M.
    El Diwani, Hoda, I
    [J]. ARCHIV DER PHARMAZIE, 2019, 352 (11)
  • [4] Novel potent substituted 4-amino-2-thiopyrimidines as dual VEGFR-2 and BRAF kinase inhibitors
    Abdel-Mohsen, Heba T.
    Omar, Mohamed A.
    El Kerdawy, Ahmed M.
    Mahmoud, Abeer E. E.
    Ali, Mamdouh M.
    El Diwani, Hoda I.
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019, 179 : 707 - 722
  • [5] Laccase-Catalyzed Domino Reaction between Catechols and 6-Substituted 1,2,3,4-Tetrahydro-4-oxo-2-thioxo-5-pyrimidinecarbonitriles for the Synthesis of Pyrimidobenzothiazole Derivatives
    Abdel-Mohsen, Heba T.
    Conrad, Juergen
    Beifuss, Uwe
    [J]. JOURNAL OF ORGANIC CHEMISTRY, 2013, 78 (16) : 7986 - 8003
  • [6] Novel benzimidazole-pyrimidine conjugates as potent antitumor agents
    Abdel-Mohsen, Heba T.
    Ragab, Fatma A. F.
    Ramla, Mostafa M.
    El Diwani, Hoda I.
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2010, 45 (06) : 2336 - 2344
  • [7] Multiple Binding Modes of Inhibitors to Carbonic Anhydrases: How to Design Specific Drugs Targeting 15 Different Isoforms?
    Alterio, Vincenzo
    Di Fiore, Anna
    D'Ambrosio, Katia
    Supuran, Claudiu T.
    De Simone, Giuseppina
    [J]. CHEMICAL REVIEWS, 2012, 112 (08) : 4421 - 4468
  • [8] Benej M, 2014, SUBCELL BIOCHEM, V75, P199, DOI 10.1007/978-94-007-7359-2_11
  • [9] Combining the tail and the ring approaches for obtaining potent and isoform-selective carbonic anhydrase inhibitors: Solution and X-ray crystallographic studies
    Bozdag, Murat
    Ferraroni, Marta
    Nuti, Elisa
    Vullo, Daniela
    Rossello, Armando
    Carta, Fabrizio
    Scozzafava, Andrea
    Supuran, Claudiu T.
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY, 2014, 22 (01) : 334 - 340
  • [10] Carta F, 2014, FUTURE MED CHEM, V6, P1149, DOI [10.4155/FMC.14.68, 10.4155/fmc.14.68]